Top Markets
#1 Islamic Coin Islamic Coin +154.35%
#2 PulseChain PulseChain +49.22%
#3 BOOK OF MEME BOOK OF MEME +24.70%
#4 edgeX edgeX +16.67%
#5 RedStone RedStone +16.49%
#6 Starpower Starpower +15.93%
#7 Bio Protocol Bio Protocol +12.37%
#8 Lighter Lighter +12.26%
#9 Monad Monad +11.98%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.93%
Coin of the day
Islamic Coin Islamic Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Immunotech Biopharm Ltd Immunotech Biopharm Ltd

Immunotech Biopharm Ltd

6978
Rang in Aktien #27805
Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in... Immunotech Biopharm Ltd operates as a biopharmaceutical firm specializing in cellular immunotherapy. Its primary activities involve the investigation, development, and market introduction of T cell-based immunotherapy solutions for various cancers within the People's Republic of China. The company's flagship product, EAL, is a multi-target cellular immunotherapy currently undergoing Phase II clinical trials for the purpose of preventing liver cancer recurrence after surgery. Furthermore, Immunotech Biopharm is conducting both preclinical and clinical research on EAL for its potential use in treating lung cancer, glioma, gastric cancer, and colorectal cancer. Other pipeline assets include the 6B11-OCIK injection, which is in Phase I trials for ovarian cancer; the CAR-T-19 injection product, targeting B-cell acute lymphoblastic leukaemia; and a range of TCR-T cell products designed for solid tumor treatment. Established in 2006, the company's main office is located in Beijing, China.
Aktienkurs
$0.0492516
Marktkapitalisierung
$30.41M
Veränderung (1 Tag)
1.32%
Veränderung (1 Jahr)
-91.28%
Land
CN
Handel Immunotech Biopharm Ltd (6978)

Kategorie

Healthcare
Gewinn für Immunotech Biopharm Ltd (6978)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von Immunotech Biopharm Ltd betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Immunotech Biopharm Ltd von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH